-
Mashup Score: 2The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay - 4 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Rana R. McKay, Medical Oncologist, Associate Professor, University of California, San Diego, San Diego, CA Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Investigational Urine Test Better at Finding Prostate Cancer - 4 day(s) ago
MyProstateScore 2.0 (MPS2) proved more accurate at detecting prostate cancer than PSA and other biomarkers, researchers reported, sparing men more invasive testing, such as prostate biopsies and MRI (JAMA Oncol 2024 Apr 18). The test was designed to specifically identify higher-grade disease by measuring expression of 18 genes most often found in the presence of significant cancers. In 743 men with elevated PSA levels, using MPS2 would have avoided 35% to 42% of prostate biopsies without missing diagnoses of clinically significant disease, whereas existing biomarker testing could have avoided only 15% to 30% of biopsies. The improvement was more dramatic in men who previously had negative biopsies—the rate of unnecessary biopsies dropped to between 46% to 51% compared with 9% to 21% for existing tests. One limitation of the trial, however, was that only 13% of participants were African American, a population known to have a higher prevalence of prostate cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1New Theranostic Targets in Prostate Cancer: What Do We Do to Keep Up? - Hans David Ulmert - 4 day(s) ago
In a conversation with Phillip Koo, David Ulmert discusses the limitations and future directions of theranostics in prostate cancer, focusing on Lutetium-177 PSMA. Dr. Ulmert identifies the off-target effects and variable expression of PSMA as key challenges. He suggests broadening the theranostic approach beyond radioligands to include options like ADCs, CAR-T, or bispecifics. Highlighting…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1High-Risk Prostate Cancer: 80Gy + ADT Extends Survival Without Added Toxicity - Christophe Hennequin - 4 day(s) ago
Leslie Ballas and Christophe Hennequin explore the findings of the GETUG-AFU 18 randomized trial, which evaluated the impact of radiotherapy dose escalation in high-risk prostate cancer patients receiving long-term androgen deprivation therapy (ADT). Conducted between 2009 and 2013, the trial randomized 500 patients to receive either 70 Gy or 80 Gy, revealing significant improvements in…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5
Judd Moul discusses a study focusing on the mortality risk associated with androgen deprivation therapy (ADT) in Black versus white patients with prostate cancer. The study, a comprehensive analysis of a large cohort, indicates that African-American ethnicity may be protective for survival in both castrate-resistant and castrate-sensitive prostate cancer. This contradicts earlier perceptions,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Analyzing real-world impact of race on ADT mortality in #ProstateCancer. @JuddMoul @DukeHealth and @SamWashUro @UCSFUrology shed light on racial disparities and survival benefits, inviting further investigation into the underlying causes and implications > https://t.co/Os59bnZmDT https://t.co/vcxFGFXYdf
-
-
Mashup Score: 7
At the 2024 UCSF-UCLA PSMA Conference, Louise Emmett explores the interaction between PSMA and androgen receptors in prostate cancer, focusing on their role across different disease states and the impact on treatment and imaging. Dr. Emmett highlights the ENZA-P trial, a study investigating the combination of Enzalutamide with Lutetium PSMA in metastatic castrate-resistant prostate cancer,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell - 6 day(s) ago
Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Goebell’s study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. The review, incorporating data from 344,000 patients globally, examines the application of doublets and triplets in…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 23
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC The Current Treatment Landscape in Metastatic Prostate Cancer – Andrew Armstrong Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Andrew Armstrong, MD, Professor of Medicine, Professor in Surgery, Professor in Pharmacology and Cancer Biology, Director of Research, Duke…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5The Role of Urologists in Managing De Novo Metastatic Prostate Cancer - Benjamin Lowentritt - 6 day(s) ago
Alicia Morgans engages in a discussion with Benjamin Lowentritt, focusing on comprehensive care for prostate cancer patients, particularly those with de novo metastatic hormone-sensitive disease. Dr. Lowentritt shares a patient case illustrating the challenges and strategies in managing such cases over time. They emphasize the importance of multidisciplinary teams and seamless communication…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1ADC FG-3246 May Show Promise in Advanced Prostate Cancer - 7 day(s) ago
Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic castration-resistant prostate cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
The critical intersection of androgen receptor pathways and cell cycle regulation in #ProstateCancer therapy. @DrRanaMcKay @UCSanDiego joins @CaPsurvivorship as part of this Independent Medical Education Initiative supported by @LoxoLillyOnc > https://t.co/hnirLkwSGo https://t.co/Vo1zQNvR7T